Issues of concern in treating patients with anemia during maintenance hemodialysis

doi:10.3877/cma.j.issn.2095-3216.2014.03.004

Abstract

Abstract:

Anemia is an important clinical manifestation of patients receiving maintenance hemodialysis, and is an independent risk factor for poor prognosis. Effective treatment of anemia is an essential part of efforts to improve the quality of long-term survival of hemodialysis patients. Currently, the recommended hemoglobin target level is 110-120 g/L. Significant fluctuation of hemoglobin level may affect the mortality of hemodialysis patients. The poor response of patients to treatment of erythropoietic stimulating agents (ESA) is associated with iron deficiency, chronic blood loss, hyperparathyroidism, fibrous osteitis,aluminum poisoning, hemolysis, inadequate dialysis, and other factors. In hemodialysis patients,hemoglobin should be monitored frequently, and combined therapy of ESA with intravenous iron administration should be used to correct anemia. For treatment of anemia in hemodialysis patients, not only should the guidelines-recommended target level of hemoglobin be reached in a stable pattern, but the hemoglobin level also should be successfully maintained within the target range.

Key words: Hemodialysis, Anemia, Treatment

Hongli Lin, Jing Wang. Issues of concern in treating patients with anemia during maintenance hemodialysis[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2014, 03(03): 133-136.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2014.03.004

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2014/V03/I03/133

References 22

1	Foley RN, Parfrey PS, Harnett JD, et al. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease[J]. Am J Kidney Dis,2006,28(1):53-61.
2	Teruel-Briones JL, Fernández-Lucas M, Rivera-Gorrin M, et al.Progression of residual renal function with an increase in dialysis:haemodialysis versus peritoneal dialysis [J]. Nefrologia, 2013, 33(5):640-649.
3	Verdalles U, Abad S, Vega A, et al. Factors related to the absence of anemia in hemodialysis patients[J]. Blood Purif,2011,32(1):69-74.
4	Port FK, Pisoni RL, Bommer J, et al. Improving outcomes for dialysis patients in the international dialysis outcomes and practice patterns study [J]. Clin J Am Soc Nephrol, 2006, 1(2): 246-255.
5	Locatelli F, Pisoni RL, Combe C, et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study(DOPPS) [J]. Nephrol Dial Transplant,2004,19(1):121-132.
6	KDIGO Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease [J]. Kidney Inter Suppl,2012,2(4):279-335.
7	肾性贫血诊断与治疗中国专家共识[J]. 中华肾脏病杂志,2013,29(5):389-392.
8	Locatelli F, Covic A, Eckardt K-U, et al, Anaemia management in patients with chronic kidney disease:a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP)[J]. Nephrol Dial Transplant,2009,24(2):348-354.
9	Macdougall IC, Geisser P. Use of intravenous iron supplementation in chronic kidney disease [J]. Iran J Kidney Dis,2013,7(1):9-22.
10	US Renal Data System. Annual data report [DB/OL]. 2012:152-164. http: / /www. usrds. org/ atlas12.aspx.
11	Garrancho JM, Kirchgessner J, Arranz M, et al. Haemoglobin level and vascular access survival in haemodialysis patients [J]. Nephrol Dial Transplant,2005,20(11):2453-2457.
12	Pharommintikul A, Haas SJ, Elsik M, et al. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis [J]. Lancet 2007,369(9559):381-388.
13	Koulouridis I, Alfayez M, Thomas A, et al. Dose of erythropoiesisstimulating agents and adverse outcomes in CKD: a metaregression analysis [J]. Am J Kidney Dis,2013,61(1):44-56.
14	Yang W,Israni RK,Brunelli SM,et al. Hemoglobin variability and mortality in ESRD [J]. J Am Soc Nephrol, 2007,18(12): 3164-3170.
15	Ebben JP, Gilbertson DT, Foley RN, et al. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations [J]. Clin J Am Soc Nephrol, 2006, 1(6): 1205-1210.
16	Gaweda AE, Aronoff GR, Jacobs AA, et al. Individualized anemia management reduces hemoglobin variability in hemodialysis patients[J]. J Am Soc Nephrol,2014,25(1):159-66.
17	Lau JH, Gangji AS, Rabbat CG, et al. Impact of haemoglobin and erythropoietin dose changes on mortality: a secondary analysis of results from a randomized anaemia management trial [J]. Nephrol Dial Transplant,2010,25(12):4002-4009.
18	Servilla KS, Singh AK, Hunt WC, et al. Anemia mananegement and association of race with mortality and hospitalization in a large not-for -profit dialysis organization. Am J Kidney Dis, 2009, 54(3):498-510.
19	Kainz A, Mayer B, Kramar R, Oberbauer R. Association of ESA hypo-responsiveness and haemoglobin variability with mortality in haemodialysis patients [J]. Nephrol Dial Transplant, 2010, 25(11):3701-3706.
20	Kshirsagar AV, Freburger JK, Ellis AR, et al. The comparative short-term effectiveness of iron dosing and formulations in US hemodialysis patients [J]. Am J Med, 2013, 126(6): 5411-5414.
21	Rottembourg J, Sonigo Y, Dansaert A, et al. Intravenous iron during predialysis period improves anemia management and cardiovascular parameters in incident hemodialysis patients [J].Nephrol Ther,2013,9(7):486-493.
22	Vaziri ND. Understanding iron: promoting its safe use in patients with chronic kidney failure treated by hemodialysis. Am J Kidney Dis,2013,61(6):992-1000.

[1]	Baicheng Yi, Xuguang Li, Rongrong Wang, Xinxuan Wang. Treatment of calcified root canals in upper anterior teeth using digital 3D-printing guides：A clinical report of two cases [J]. Chinese Journal of Stomatological Research(Electronic Edition), 2024, 18(06): 385-390.
[2]	Huayue Yan, Zixiang Liu, Shaobo Zhou. Research progress of phosphoenolpyruvate carboxykinase-1 in malignant tumors [J]. Chinese Archives of General Surgery(Electronic Edition), 2024, 18(06): 452-456.
[3]	Huazhi Li, Guang Cao, Diangang Liu, Yajing Zhang. Clinical comparison of descending hepatectomy with different approaches for primary hepatocellular carcinoma [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 52-55.
[4]	Hao Chen, Meng Wang. Advances in clinicopathological features and treatment options of sig-ring cell carcinoma of the stomach [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 108-111.
[5]	Yuefang Xu, Wang Liu, Miaotian Zeng, Yushu Guo. Clinical efficacy of polymyxin B and polymyxin E in the treatment of surgical multi-drug resistant infections Security analysis [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 700-703.
[6]	of Organ Transplantation of Chinese Medical Association Branch. Chinese practice guidelines for diagnosis and treatment of ischemic-type biliary lesion after liver transplantation [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 739-748.
[7]	Qiusheng Wang. Diagnosis and treatment strategy for benign biliary diseases [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 779-782.
[8]	Anti-Cancer Association China, Committee of Colorectal Cancer CACA the. CACA guidelines for holistic integrative management of anal cancer （2024 Edition） [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2024, 13(06): 441-449.
[9]	Xuefeng Zhou, Zheyi Dong, Zhe Feng, Guangyan Cai, Xiangmei Chen. Formulation protocol of guidelines for diagnosis and treatment of diabetic kidney disease with integrated traditional Chinese and Western medicine [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(06): 301-305.
[10]	Bin Shi, Yuan Si. Effect of Yiqiheluo formula combined with valsartan in the treatment of IgA nephropathy with deficiency of both qi and yin plus blood stasis syndrome [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(06): 306-312.
[11]	Junxia Du, Xiaolin Zhao, Haoran Wang, Zhiyuan Gao, Manqian Wang, Nanxi Wan, Dong Zhang, Xiaonan Ding, Qinqin Ren, Yingjie Duan, Li Tang, Hanyu Zhu. High throughput sequencing analysis of intestinal microbiome in hemodialysis patients with type 2 diabetes [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(06): 313-320.
[12]	Shaoqing Zhang, Yufeng Lv, Haixia Dong. The predictive effect of neutrophil percentage-to-albumin ratio for all-cause mortality in maintenance hemodialysis patients [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(06): 321-326.
[13]	Wenkai Guo, Pengcheng Ji, Jingru Bi, Yuansheng Xie. Ten treatment measures for IgA nephropathy [J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2024, 13(06): 327-333.
[14]	Beibei Wang, Zhenyi Cui, Jing Wang, Hanyan Wang, Hongzhi Lv, Xiuting Li. Development and Validation of postoperative anemia prediction model in elderly patients with intertro-chanteric fracture [J]. Chinese Journal of Geriatric Orthopaedics and Rehabilitation(Electronic Edition), 2024, 10(06): 355-362.
[15]	Tianyu Wu, Zixuan Liu, Puxin Yang, Siming Jia, Kai Ding, Xiaodong Cheng, Yonglong Li, Wei Chen, Hongzhi Lyu, Qi Zhang. Progress in Conservative Treatment of Lumbar Disc Herniation [J]. Chinese Journal of Geriatric Orthopaedics and Rehabilitation(Electronic Edition), 2024, 10(06): 379-384.

Please choose a citation manager

Content to export